Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 7/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | CLK2 | P49760 | 4/20 | 0.47 |
| ▸ | CLK3 | P49761 | 4/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.42 |
| ▸ | CLK1 | P49759 | 2/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400110 | 1.00 | MELK (0.48) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL26175113 | 0.96 | MELK (0.45) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL30400196 | 0.96 | MELK (0.45) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL30399215 | 0.93 | MELK (0.46) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL26175151 | 0.93 | MELK (0.46) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL26175152 | 0.88 | DYRK1A (0.48) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL30399094 | 0.88 | DYRK1A (0.48) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL26175154 | 0.87 | MELK (0.46) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL30399574 | 0.87 | MELK (0.46) | MELKDYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL30400105 | 0.85 | DYRK1A (0.52) | DYRK1AGSK3BDYRK1BCLK1DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | MELK 460/4885DYRK1A 1/4885GSK3B 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.